Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent and Sequential Carboplatin and Paclitaxel With Adjuvant Radiotherapy for High Risk Endometrial Cancer
NCT03935256Phase 2Active, not recruiting
- Sponsor
- Loyola University Chicago
- Start
- Mar 2019
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, Paclitaxel Micelles for Injection in endometrial cancer (EC), sponsored by Loyola University Chicago. Started Mar 2019; status: active, not recruiting.
02
Drugs
carboplatinPaclitaxel Micelles for Injection
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03935256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935256.